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An effective graft-versus-host disease (GVHD) preventative approach that preserves the graft-versus-tumor
effect after allogeneic hematopoietic stem cell transplantation (HSCT) remains elusive. Standard GVHD pro-
phylactic regimens suppress T cells indiscriminately and are suboptimal. Conversely, post-transplantation
high-dose cyclophosphamide selectively destroys proliferating alloreactive T cells, allows the expansion of
regulatory T cells, and induces long-lasting clonal deletion of intrathymic antihost T cells. It has been suc-
cessfully used to prevent GVHD after allogeneic HSCT. Bortezomib has antitumor activity on a variety of
hematological malignancies and exhibits a number of favorable immunomodulatory effects that include in-
hibition of dendritic cells. Therefore, an approach that combines post-transplantation cyclophosphamide and
bortezomib seems attractive. Herein, we report the results of a phase I study examining the feasibility and
safety of high-dose post-transplantation cyclophosphamide in combination with bortezomib in patients
undergoing allogeneic peripheral blood HSCT from matched siblings or unrelated donors after reduced-
intensity conditioning. Cyclophosphamide was given at a ﬁxed dose (50 mg/kg on days þ3 and þ4). Borte-
zomib dose was started at .7 mg/m2, escalated up to 1.3 mg/m2, and was administered on days 0 and þ3.
Patients receiving grafts from unrelated donors also received rabbit antithymocyte globulin. The combination
was well tolerated and allowed prompt engraftment in all patients. The incidences of acute GVHD grades II to
IV and grades III and IV were 20% and 6.7%, respectively. With a median follow-up of 9.1 months (range, 4.3 to
26.7), treatment-related mortality was 13.5% with predicted 2-year disease-free survival and overall survival
of 55.7% and 68%, respectively. The study suggests that the combination of post-transplantation cyclophos-
phamide and bortezomib is feasible and may offer an effective and practical GVHD prophylactic regimen. The
combination, therefore, merits further examination.
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Research reports suggest that the incidence of acute and
chronic GVHD has increased in recent years [3,4]. Addition-
ally, the current standard regimens impair the graft-versus-
tumor (GVT) effect, delay immune reconstitution, and are
burdensome [5,6].
Cyclophosphamide, administered in high doses early after
transplantation, allows for long-term tolerance by inducing
selective depletion of proliferating host-reactive T cells,
promoting regulatory T cells, and producing long-lasting
intrathymic clonal deletion of antihost T cells (reviewed by
Luznik et al.) [7]. When used alone after matched related and
unrelated donor bone marrow HSCT, cyclophosphamide
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impairing engraftment (reviewed in [8]). Furthermore, its
selective activity targeting proliferating rather than resting
cells suggests that it may preserve the GVT effect and permit
rapid immune reconstitution [9].
Bortezomib occupies proteasomal proteolytic sites, dis-
rupts mitochondrial function, and produces endoplasmic
stress in dendritic antigen-presenting cells and T cells [10-
12]. Consequently, cells treated with bortezomib exhibit a
decreased expression of maturation and functional markers,
reduced ability to produce proinﬂammatory cytokines,
impaired mobilization, cell cycle arrest, and apoptosis [11,13-
16]. Other beneﬁcial characteristics of bortezomib include a
more pronounced proapoptotic activity on alloreactive Tcells
[13] and an ability to preserve regulatory T cells and foster
the emergence of a distinct population of suppressor T cells
[17]. Several mouse models and clinical trials have shown
that bortezomib is active in preventing GVHD when given as
a short course after transplantation [18-21]. Bortezomib is
also active in a variety of hematological malignancies and
enhances natural killer celleinduced tumor cytotoxicity
[22,23].
Therefore, we wanted to explore the feasibility and safety
of combined high-dose post-transplantation cyclophospha-
mide with bortezomib after allogeneic HSCT. Our aim was to
concomitantly target dendritic and T cells. Herein, we report
the results of this phase I study.MATERIALS AND METHODS
Eligibility
Patients with hematological malignancies undergoing allogeneic pe-
ripheral blood HSCT from related or unrelated donors after reduced-
intensity conditioning were considered. Donors had to be allele-matched
to the recipient at HLA loci A, B, C, and DRB1. Inclusion criteria included
age  18 years, Karnofsky performance status  70%, creatinine clearance
> 40 mL/minute/1.73 m2, total bilirubin < 1.5 mg/dL, transaminases < 2
times the upper limit of normal, left ventricular ejection fraction > 40%,
corrected carbon monoxide diffusing capacity > 50%, negative pregnancy
test, and negative human immunodeﬁciency virus test. Eligible patients
had to be able to provide informed consent, agree to prevent pregnancy for
at least 30 days after the last dose of bortezomib, and show no evidence of
progressive bacterial, viral, or fungal infection despite adequate treatment
before the initiation of the preparative regimen. Exclusion criteria included
peripheral neuropathy  grade 2, uncontrolled angina, myocardial infarc-
tion within 6 months from enrollment, electrocardiographic evidence of
acute ischemia, severe uncontrolled ventricular arrhythmias, active con-
duction system abnormalities, a New York Heart Association class III or IV
heart failure, serious medical or psychiatric illness that could interfere with
participation, and another malignancy within 3 years of enrollment (with
the exception of a completely resected basal or squamous cell carcinoma of
the skin, treated in situ malignancy, or low-risk curatively treated prostate
cancer). Patients with hypersensitivity to bortezomib, boron, or mannitol
were also excluded. The study was approved by the institutional
review boards (Roger Williams Medical Center, Providence, RI and
Spectrum Health, Grand Rapids, MI) in accordance with federal regulations
and the Declaration of Helsinki. All patients signed written informed
consent before enrollment in the study. This trial was registered at
ClinicalTrials.gov, identiﬁer: NCT01860170.Figure 1. Treatment scheme. MUD indConditioning Regimen and Supportive Care
As shown in Figure 1, patients received a reduced-intensity conditioning
regimen consisting of ﬂudarabine 30 mg/m2/day (days 7 to 2) and
busulfan (.8 mg/kg) every 6 hours 8 doses for a total of 6.4 mg/kg (days3
to 2). Patients receiving grafts from unrelated donors also received rabbit
antithymocyte globulin (rATG) (Thymoglobulin, Sanoﬁ, Laval, Canada) 5 or 8
mg/kg cumulative dose per institutional practices. The ﬁrst 4 patients
received 2 mg/kg/day given on days 4 to 1. The remaining 4 patients
received 1 mg/kg, 1.5 mg/kg, and 2.5 mg/kg on days 4, 3, and 2,
respectively. Each rATG dosewas rounded to the nearest 25mg vial. The graft
source was ﬁlgrastim-mobilized peripheral blood stem cells with a required
minimumdose of CD34þ cells of 2106/kg andno upper limit. The studywas
designed to enroll patients in a standard 3 plus 3 design. Cyclophosphamide
was administeredat aﬁxeddoseof 50mg/kg/day i.v.with forcedhydrationon
days þ3 and þ4. Bortezomib was given at escalating doses in 3 consecutive
cohorts (.7,1, and 1.3mg/m2) administered i.v. 6 hours after graft infusion and
72hours thereafter if nodose limiting toxicity (DLT) occurred in1outof 3or
2 out of 6 patients. DLT was deﬁned as any grade 3 or 4 nonhematologic
toxicity, grade  2 hyperbilirubinemia, or graft failure. Antimicrobial pro-
phylaxiswas administeredper institutional standardpractices. Acyclovirwas
started on dayþ5 in the ﬁrst 6 patients andwith the start of conditioning for
the remaining patients. All patients received ﬁlgrastim 5 mg/kg starting on
day þ7. Quantitative cytomegalovirus (CMV) PCR was monitored weekly
starting at engraftment and continued until at least day þ100. Epstein-Barr
virus and adenovirus PCR were monitored in patients receiving rATG.
Adverse Events and Patient Monitoring
Patients were followed prospectively for adverse events from the initial
dose of bortezomib and until 30 days from the last dose. All adverse side
effects were graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events version 3.0. Neutrophil engraftment
was deﬁned as achieving an absolute neutrophil count  .5  109/L for 3
consecutive measurements on different days. The ﬁrst of the 3 days was
considered the day of neutrophil engraftment. Platelet engraftment was
deﬁned as a platelet count  20  109/L for 3 consecutive days without
platelet transfusion for 7 days. The ﬁrst of the 3 days was considered the day
of platelet engraftment. Donor chimerism was ﬁrst assessed at neutrophil
engraftment. Graft failure was deﬁned as lack of neutrophil engraftment by
dayþ22 and absence of donor chimerism> 50% by dayþ45. Secondary graft
failure was deﬁned as persistent decline in neutrophil count to < .5  109/L
and donor chimerism < 5% in the absence of disease relapse. Patients were
assessed for both acute and chronic GVHD. The clinical diagnosis of GVHD
was conﬁrmed by histology whenever possible. The ﬁrst day of acute
or chronic GVHD of a certain grade was used to calculate the cumu-
lative incidence for that grade. Acute GVHD was graded according to the
modiﬁed Keystone criteria. Upper gastrointestinal GVHD was considered
stage 1. Chronic GVHD grading was based on the National Institute of Health
criteria.
Study Design and Statistical Analysis
The primary objective of this phase I study was to determine the
feasibility and safety of bortezomib administered after transplantation in
conjunctionwith a ﬁxed high-dose cyclophosphamide as GVHD prophylaxis.
Secondary objectives were to determine the incidence of graft failure, acute
and chronic GVHD, treatment-related mortality (TRM), progression-free
survival (PFS), and overall survival (OS). TRM was deﬁned as death
without evidence of recurrent disease. PFS and OS were estimated from day
0 according to the Kaplan-Meier method.
RESULTS
Patient Characteristics
Patient characteristics and outcomes are summarized in
Table 1. Fifteen patients were enrolled: 3 in each of cohorts 1icates matched unrelated donor.
Table 1
Patient Characteristics and Outcomes
Patient
ID



























1 56 F CLL low 90 PR1 8.24 .7 MRD þ/þ 0 0 0 0 None 26.7 m; NED
2 65 F MDS high 90 PR1 6.19 .7 MUD / 1 0 0 I None Steroids low dose,
short course
30 m; NED
3 60 F FL low 80 PR4 10.1 .7 MUD þ/þ CMV reactivation,
CNS toxoplasmosis,
and G-R HSV






















6 47 M MM int 80 PD (4 lines
of therapy)








7 51 M CLL low 90 PR3 2.76 1.3 MRD / 1 0 0 I None 23.9 m; NED
8 54 M MDS high 100 CR1 7.11 1.3 MRD þ/þ CMV reactivation 1 0 0 I None Progression
at 10.7 m;
alive at 14.5 m
9 55 M CLL low 90 PR3 5.2 1.3 MRD þ/þ CMV reactivation 3 0 0 II None Steroids 10.6 m; NED
10 65 F MDS very high 80 PD (1 line
of therapy)
2.69 1.3 MRD þ/ CMV and
EBV reactivation








11 57 M AML low 100 CR2 4.55 1.3 MUD þ/þ CMV and EBV
reactivation
0 0 0 0 None Progression
at 9.1 m;
alive at 9.1 m
12 43 F AML low 100 CR2 5 1.3 MUD þ/ BK virus
hemorrhagic
cystitis
0 0 0 0 * 7.1 m; NED
13 43 M DLBCL int 90 PR3 5.01 1.3 MUD þ/ CMV reactivation 3 0 0 II * Steroids Progression
at 2.6 m;
alive at 5.9 m
14 66 M MDS high 90 PD (2 lines
of therapy)
5 1.3 MRD þ/ CMV reactivation 0 3 0 III * Steroids and CSA
for acute GVHD
5 m; NED
15 37 M AML int 90 CR1 7.12 1.3 MUD þ/þ 2 0 0 I * Steroids low dose,
short course
4.3 m; NED
DRI indicates disease risk index; KS, Karnofsky status; Bor, bortezomib; D, donor; R, recipient; GI, gastrointestinal; F, female; CLL, chronic lymphocytic leukemia; PR, partial remission; MRD, matched related donor; NED, no
evidence of disease; MUD, matched unrelated donor; FL, follicular lymphoma; CNS, central nervous system; G-R HSV, genito-rectal herpes; MMF, mycophenolate mofetil; AML, acute myelogenous leukemia; CR, complete



















A.-S. Al-Homsi et al. / Biol Blood Marrow Transplant 21 (2015) 1315e13361318and 2 and 9 in cohort 3, as no DLT occurred in any patient.
The ﬁrst 7 patients were enrolled at Roger Williams Medical
Center and the remaining 8 at Spectrum Health. The median
age was 56 years (range, 37 to 66). There were 7 females and
8 males. Four patients had acute myelogenous leukemia, 5
myelodysplastic syndrome (MDS), 3 chronic lymphocytic
leukemia, and 1 each of follicular lymphoma, multiple
myeloma (MM), and diffuse large B cell lymphoma. Disease
risk index was low in 6, intermediate in 4, and high or very
high in 5 patients. At the initiation of conditioning, 2 patients
with acute myelogenous leukemia were in ﬁrst and 2 in
second complete remission. Four of 5 patients with MDS had
active disease. The patient with MM had progressive disease
after 2 autologous transplantations. The patient with diffuse
large B cell lymphoma had relapsed within 1 year after
autologous transplantation but remained chemo-sensitive.
All the remaining patients were in partial remission. All pa-
tients received ﬁlgrastim-mobilized peripheral blood stem
cells. The infused median dose of CD34þ cells was 5.01106/
kg (range, 2.69 to 13.32). All patients completed the planned
treatment. There was 1 protocol violation with a patient
receiving a 5-day course of steroids for a biopsy-proven drug
eruption.
Engraftment and GVHD
Engraftment was prompt in all patients. Median time to
neutrophil engraftment was 16 days (range, 13 to 23). Two
patients died before achieving platelet engraftment. The ﬁrst
patient had acyclovir-resistant herpes genitalis and CMV
reactivation requiring protracted therapy with foscarnet and
died on day þ150 from respiratory syncytial virus and
candida glabrata pneumonitis. The second patient died on
day þ200 because of acute sepsis in the setting of chronic
GVHD. Median time to platelet recovery in the remaining
patients was 28 days (range, 15 to 38). All patients achieved
full donor chimerism by day þ28, except for 1 patient who
had residual chronic lymphocytic leukemia at engraftment
and did not reach full donor chimerism until day þ118 after
developing acute GVHD. No patient developed secondary
graft failure.
The overall incidence of acute GVHD was 67% for all
grades, 20% grades II to IV, and 6.7% for grades III and IV.
There was no grade IV GVHD and only 1 patient developed
visceral acute GVHD. Overall, 7 patients received systemic
steroids for acute GVHD; 4 of them received abbreviated
course of prednisone < .5 mg/kg for grade I disease involving
the face. Three of 12 (25%) patients with follow-up > 6
months developed chronic GVHD; 1 moderate and 2 severe.
Overall, 6 patients (40%) have not required any secondary
immunosuppressive therapy thus far.
Nonhematologic Toxicity and Adverse Events
Two patients developed extensive herpetic genito-rectal
ulcers; 1 had prior history of recurrent ﬂares with
acyclovir-resistant disease. When institutional guidelines
were changed to start acyclovir at the beginning of condi-
tioning, as opposed to day þ5, no other cases were noted.
Eight patients developed CMV reactivation and received
preemptive therapy. No CMV disease occurred. Three pa-
tients developed Epstein-Barr virus reactivation, of whom 2
required preemptive therapy with rituximab. One patient
developed BK viruseinduced hematuria and 1 patient
developed central nervous system toxoplasmosis. One pa-
tient, mentioned above, developed respiratory syncytial vi-
rus and candida glabrata pneumonia. All other side effectswere grade 1 or 2. The most common side effects were
gastrointestinal and transient elevation of liver function
tests. One patient experienced rigors after cyclophospha-
mide infusion. Additional events included syncope (n ¼ 1),
orthostatic hypotension (n ¼ 2), and venous thromboem-
bolism (n ¼ 2).
Relapse and Mortality
There was no mortality by day þ100. With a median
follow-up of 9.1 months (range, 4.3 to 26.7), 2 (13.5%)
treatment-related deaths occurred on days þ150 and þ200.
The patient with MM and a patient with high-risk MDS died
because of progressive disease. Overall, disease relapse
occurred in 5 patients (33%) on days þ79, þ118, þ205, þ271,
and þ321. The 2-year predicted PFS and OS were 55.7% and
68%, respectively.
DISCUSSION
An optimal GVHD prevention regimen must be effective,
permit rapid immune reconstitution, and preserve the GVT
effect. The regimen should also be well tolerated and not
burdensome to use. The current pharmacologic prophylaxis,
employing different combinations of methotrexate, myco-
phenolic acid, calcineurin inhibitors, mammalian target of
rapamycin (mTor) inhibitors, and antithymocyte globulin all
aim to indiscriminately inhibit or eliminate T cells and,
therefore, fall short of meeting the above requisites. No
speciﬁc combination has proved superior [24]. A recent study
comparing the commonly used combination of tacrolimus
and methotrexate to a novel duplet of tacrolimus and siro-
limus after matched sibling donor HSCT failed to demon-
strate any signiﬁcant improvement. The incidence of grade II
to IV acute and chronic GVHDwas 34% and 43% in the control
arm and 26% and 54% in the study arm, respectively [25].
Furthermore, although oral mucositis was decreased, the
experimental combination was associated with higher inci-
dence of thrombotic microangiopathy and hepatic sinusoidal
occlusive syndrome.
Luznik et al. introduced cyclophosphamide administered
in high doses in the early post-transplantation period as
single-agent prophylaxis in patients undergoing matched
related or unrelated donor transplantation after myeloa-
blative conditioning [26]. As opposed to pan T cell suppres-
sion, cyclophosphamide activity seems selective to donor
alloreactive cells [9]. The original results were recently
conﬁrmed by Kanakry et al. in amulti-institutional trial using
bone marrow as the source of stem cells. The incidences of
grade II to IV and grade III and IV acute GVHD remained
signiﬁcant, however, at 50% and 15%, respectively [27]. The
incidence of chronic GVHD was more favorable (14%). In an
attempt to further improve the results, Solomon et al. added
sirolimus to post-transplantation cyclophosphamide for pa-
tients receiving myeloablative conditioning followed by pe-
ripheral blood HSCT from matched related or unrelated
donors [28]. The incidences of acute grade II to IV GVHD and
chronic GVHD were 46% and 31%, respectively.
Dendritic cells (DC) play a pivotal role in the early
development of GVHD and seem to be an ideal target for
GVHD prevention. Bortezomib has been shown to inhibit DC
maturation and function and possesses a number of other
favorable immunomodulatory effects (reviewed by Mohty
et al.) [29]. Koreth et al. studied bortezomib in combination
with methotrexate and tacrolimus in a high-risk group
receiving mismatched unrelated donor transplants [21]. The
incidences of acute grade II to IV and chronic GVHDwere 22%
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enhanced in comparison to historical control [21].
In the current study, we aimed to explore the feasibility of
the addition of bortezomib to a platform of post-
transplantation cyclophosphamide, a combination that
selectively targets alloreactive T cells and DC. Because we
used a reduced-intensity conditioning and peripheral blood
stem cells, we opted to add rATG in patients receiving grafts
from unrelated donors as originally described by Slavin et al.
[30]. We demonstrated that the combination does not impair
engraftment. All but 1 patient with residual disease achieved
full donor chimerism by day þ28. Accounting for the use of
peripheral blood as opposed to bone marrow grafts, the
median duration to neutrophil and platelet engraftment was
comparable to the study by Kanakry et al., where the median
times to neutrophil and platelet engraftment were 21 (range,
15 to 42) and 24 days (range, 12 to 65), respectively [27]. In
the study by Solomon et al., with peripheral blood as the
source of grafts, the median times to neutrophil and platelet
engraftment were 15 (range, 13 to 28) and 30 days (range, 16
to 164), respectively [28]. Kanakry et al. reported primary
graft failure in 5.4% of patients and secondary graft failure in
2.2% [27]. There was no primary or secondary graft failure
encountered thus far in our study. The toxicity of our
regimen was also acceptable. As mentioned, there was no
grade 3 or greater nonhematologic toxicity. The incidence of
infectious complications was also acceptable. Despite
frequent CMV reactivation, there was no CMV disease. The
primary endpoint of this phase I trial was not to evaluate the
efﬁcacy of the combination. Nevertheless, the incidence of
grade II to IV acute GVHD of 20% and grade III and IV of 6.6% is
encouraging. The incidence of gastrointestinal and hepatic
acute GVHDwas notably low.With a median follow-up of 9.1
months (range, 4.3 to 26.7) the TRM and the predicted 2-year
PFS and OS were within the expected range.
Many questions remain to be addressed. Studies in mice
suggest that prolonged administration of bortezomib after
allograft is associated with increased incidence of GVHD-
dependent gastrointestinal toxicity [31]. A recent study
showed that this may be due to paradoxical increase in the
production of interleukin-1b (IL-1b) by DC [32]. Although
incubating DC with bortezomib before immunogenic stim-
ulation decreases IL-1b production, the addition of bortezo-
mib to already stimulated cells has paradoxical effect. Koreth
et al. administered the last dose of bortezomib on dayþ7 and
did not report increased incidence of acute GVHD [21].
However, based on the above concern, we elected to
administer the last injection on day þ3. Finally, the fact that
cyclophosphamide activity requires active proliferation of
alloreactive T cells must also be taken into account when
using it as a platform in combination with other drugs that
may potentially impede T cell proliferation and could
potentially abrogate cyclophosphamide activity. We thought
that the effect of bortezomib on DC would likely be incom-
plete and that the early proliferation of T cells would not be
entirely prevented. Consequently, we did not delay the
administration of the ﬁrst dose of bortezomib until after
cyclophosphamide. Furthermore, we have previously re-
ported that the combination of post-transplantation cyclo-
phosphamide and bortezomib decreases donor DC-induced
T cell proliferation in mixed lymphocyte reaction and that
this effect is detectable up to day þ21 [33]. This suggests that
the combination efﬁciently deletes T cells that are capable of
proliferating in response to host antigens. We also felt that
the delayed effects of cyclophosphamide on intrathymichost-reactive T cells and regulatory T cells are equally
important mechanisms of action of cyclophosphamide and
are unlikely to be affected by the administration of borte-
zomib. Future studies must examinewhether the early use of
bortezomib before graft infusion can render its prolonged
administration safe and allow exploiting its antitumor ac-
tivity to reduce relapse [23]. The optimal schedule and
timing of bortezomib administration in relation to cyclo-
phosphamide must also be studied.
Like post-transplantation cyclophosphamide alone, our
regimen allows patients to complete GVHD prevention by
day þ4 and alleviates the need for patients’ strict compli-
ance, concerns about drug interaction, and burden of blood
level monitoring when standard pharmacologic agents are
used. The regimenmight also be useful in patients with renal
failure where the use of calcineurin inhibitors has been
associated with dismal outcomes [34].
Our study has several limitations. Our patient population
is small and the diseases treated and graft source were het-
erogeneous. Moreover, we need to be cautious when we
compare our results to those by Luznik et al. [26] and
Kankary et al. [27]. Those studies used myeloablative con-
ditioning and their GVHD prophylaxis did not include rATG.
The addition of rATG in our patients who received grafts from
unrelated donors (8 of 15) raises ambiguity as to the degree
of contribution of bortezomib in the prevention of GVHD.
Our study was designed as a feasibility trial and, therefore,
the small number of patients enrolled and short follow-up
preclude any conclusion with regard to the incidence of
GVHD, disease relapse, or survival.
In summary, we have demonstrated that the addition of
bortezomib to post-transplantation cyclophosphamide is
feasible and well tolerated. The data need to be conﬁrmed in
a larger study and several questions remain to be answered.
To that end, the study has been extended into a phase II trial.ACKNOWLEDGMENTS
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